Plus code Ophthalmology, Hengrui pharmaceutical has invested heavily in introducing two kinds of dry eye drugs from Germany

With the aging of population and the use of electronic screen, the incidence rate of dry eye is increasing It is urgent to develop effective drugs The author was informed that on November 7, Hengrui pharmaceutical announced that it had reached an agreement with novaliqgmbh company (hereinafter referred to as "novaliq company") to introduce novaliq company of Germany for the treatment of dry eye medicine cyclasol (0.1% cyclosporine a preparation) and nov03 (perfluorohexyloctane) Hengrui will obtain the rights of clinical development, production and marketing of these two products in China It is understood that cyclasol (0.1% cyclosporin a preparation) is an anti-inflammatory and immunomodulatory agent for the treatment of dry eye with water deficiency Currently, phase III clinical trials are being conducted in the United States In the clinical trials that have been completed in the United States, cyclosol has shown good efficacy, safety and tolerance Nov03 (perfluorohexyloctane) is a new drug with novel mechanism, which is used for the treatment of dry eye with hyperevaporation related to meibomian gland dysfunction (MGD) At present, phase II clinical practice has been completed in the United States, and phase III clinical practice is planned to start by the end of 2019 Cyclasol and nov03 can improve the solubility and stability of traditional water-insoluble or unstable drugs, so that the eye drops have better solubility, stability, bioavailability, safety and comfort According to the industry, Hengrui pharmaceutical has been known by the outside world in recent years for focusing on R & D and accelerating the transformation to innovative pharmaceutical enterprises But ophthalmology is not the company's previous focus This time, Hengrui pharmaceutical and novaliq Co., Ltd have reached a cooperation to introduce two heavy-duty new drugs for the treatment of dry eye disease, which can also be described as a sufficient cost It is understood that in China, the incidence of dry eye is about 21%~30%, but the incidence rate of dry eye patients is low, and the available treatment options are limited At present, the commonly used treatment programs in China are artificial tears and hormones, and there are no products similar to the two drugs introduced by Hengrui medicine on the market The introduction of cyclasol and nov03 by Hengrui medicine is good news for Chinese patients with dry eye For the news of dry eye medicine, it is reported that sun Pharma, an Indian pharmaceutical company, recently announced the launch of cequa (cyclosporine eye solution, 0.09%) in the United States Cequa is a new kind of nano micelle formula with cyclosporine concentration of 0.09% It is a clear and transparent water solution without preservatives It can increase the production of tears when it is dripped into the eyes twice a day It is worth mentioning that cequa is also an FDA approved cyclosporine treatment drug using nano micelle (ncell) technology, which helps to improve the bioavailability and physical and chemical stability of cyclosporine and improve the permeability of eye tissue In addition, Novartis announced on May 9 this year that it would acquire the global equity of xiidra ® (lifegrade 5% eye drops), a dry eye drug of Takeda Pharmaceutical (tyo: 4502; NYSE: Tak), at the cost of $3.4 billion in upfront payments and a potential $1.9 billion milestone payment Xiidra ® is a global and current prescription drug that can simultaneously relieve dry eye symptoms and inhibit inflammation In 2018, the sales revenue reached US $400 million, an increase of about 54% year on year According to Bloomberg Intelligence, sales of the product are expected to peak at $1 billion 400 million It is understood that among the cyclosporine A eye drops currently used for the treatment of dry eye disease, the products on the market in the United States include ertasis (0.05%, emulsion) and cequa (0.09%, nano micelle aqueous solution) of solar pharmaceutical; the products on the market in Europe include ikervis (0.1%, cationic nano emulsion) of ginseng pharmaceutical There is no cyclosporine A eye drops for the treatment of dry eye in China.